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Abstract
Purpose To compare patient-triggered follow-up (PTFU) for
curatively treated colorectal cancer against traditional outpa-
tient follow-up (OPFU).
Methods Questionnaires were mailed at four time points over
one-year post-treatment to two prospectively-recruited co-
horts: A, patients entering follow-up and receiving OPFU
pre-implementation of PTFU; B, patients entering follow-up
(FU) and receiving either OPFU (B1) or PTFU (B2) post-
implementation of PTFU. Bi-variate tests were used to com-
pare patient characteristics and outcomes eight months after
entering follow-up (generic and cancer-specific quality of life
(QoL), satisfaction). Regression analysis explored associa-
tions between follow-up model and outcomes. Resource im-
plications and costs of models were compared.
Results Patients in Cohort B1 were significantly more likely to
havereceivedchemotherapy(p<0.001), radiotherapy(p<0.05),
and reported poorerQoL (p=0.001). Having a longstanding co-
morbid condition was the most important determinant of QoL
(p < 0.001); model of care was not significant. Patients were
satisfied with their follow-up care regardless of model. Health
service costs were higher in PTFU over the first year
Conclusions PTFU is acceptable to patients with colorectal
cancer and can be considered to be a realistic alternative to
OPFU for clinically suitable patients. The initial costs are
higher due to provision of a self-management (SM) pro-
gramme and remote surveillance. Further research is needed
to establish long-term outcomes and costs.
Keywords Colorectal cancer . Aftercare . Follow-up . Patient
triggered-follow-up . Remote surveillance
Introduction
Over 50% of colorectal cancer (CRC) patients survive for five
years or more [1]. With an estimated 250,000 people in the
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UK having a diagnosis of CRC, pressure is evident on follow-
up services through competing demands of new patient man-
agement, alongside growing numbers of survivors [2].
Traditionally, following treatment, patients enter routine out-
patient follow-up (OPFU) delivered bymedical clinicians, and
more recently by clinical nurse specialists (CNS) [3–6], for
surveillance to detect treatable recurrence and manage on-
going symptoms [7, 8]. Although intensive follow-up investi-
gations to detect recurrence after curative resection offer a
survival benefit for CRC, clinical examination has been
shown to be of limited value [8, 9].
Alternatives to face-to-face FU have been evaluated for
breast cancer, including primary care strategies [10], nurse-
led follow-up [11], and patient-triggered follow-up (PTFU)
[12]. For CRC, nurse-led clinics and telephone follow-up
[3–6] have been shown to be effective for delivering holistic
care and detecting treatable recurrence, alongside consultant
care. It is untenable in the long-term, however, to substitute
CNS’s for medical staff in nurse-led clinic or telephone
follow-up; the CNS workforce is not expanding at a sufficient
rate to keep pace with rising need [13]. PTFU offers a poten-
tial model to meet the needs of growing numbers of CRC
survivors [14], linking patient-initiated contact with education
to self-manage [15], and coordination by specialist colorectal
CNS’s. A service improvement project was undertaken with
the colorectal clinical team at a cancer treatment centre in
Southern England to implement PTFU for curatively treated
CRC patients, utilising a remote surveillance system [14]. As
PTFU is a novel approach to FU for CRC, a service evaluation
was undertaken.
In January 2012, after approval by hospital governance, a
PTFU remote surveillance protocol [16] was introduced
(Details in Online Resource 1). Patients enter PTFU when
ongoing symptoms are resolved, either directly after surgical
resection or following time spent in OPFU. They are invited to
attend a 4-h self-management (SM) workshop, developed by
SM researchers at Coventry University, and run by a CNS and
CRC survivor. Thereafter no further routine FU appointments
are arranged. Standard OPFU is available for patients who
require ongoing symptom management, and for those on clin-
ical trials requiring tailored follow up management plans.
Details of the care pathway for patients accessing PTFU is
in Online Resource 2. Diagnostic tests for PTFU patients are
coordinated by a colorectal CNS and administrator according
to the agreed surveillance protocol (Online Resource 1) using
a customised ITsystem. Results are reviewed by the CNS, and
when normal, a letter was sent to the patient. Abnormal results
are reviewed at the multidisciplinary meeting and further ac-
tion taken as appropriate.
Theevaluationwasconductedover theperiod followingend
of acute treatment and entering survivorship when those in FU
care can have a range of physiological, psychosocial and func-
tional needs, and individual patients differ in their health status
and response to cancer and its treatment [17]. Patient-reported
quality of life (QoL) outcomes and satisfaction with care were
compared before and after the implementation of PTFU.
Patients were followed for 12 months after ending treatment.
Detection of recurrence and survival are not being addressed.
Costs and health service utilisation were compared.
Materials and methods
Study participants
Two cohorts of patients entering follow-up were recruited
prospectively. Cohort A entered OPFU before the service
change, between April and December 2011; Cohort B entered
follow-up after the implementation of PTFU, between January
2012 and August 2013. Depending on their clinical status,
patients in Cohort B could be enrolled in either OPFU (for
ongoing symptommanagement) or PTFU. Patients were iden-
tified through hospital records and clinician referral.
Eligibility criteria were: completion of all treatment with cu-
rative intent for CRC; absence of a second cancer diagnosed
during treatment; age 18 years or over; no dementia, severe
memory loss, or learning disability preventing questionnaire
completion. Written consent was obtained.
Data collection
Data were collected by self-report using structured question-
naires that were mailed at four time points: on completion of
final curative treatment (baseline T0), 4 months later (T1),
8months later (T2), 12months later (T3). Reminderswere sent
after two, four and six weeks to non-respondents. Hospital re-
cords were used to check patient survival status prior to mail-
ings.Socio-demographic data and information about long-term
conditions(LTCs)weregatheredatbaseline.Postcodewasused
to derive the Index of Multiple Deprivation (IMD), a govern-
ment measure reflecting income, employment, housing and
othersocial indicators for localareas [18].Withconsent,clinical
records were accessed to gather details of time since diagnosis,
all types of treatments received, date of entering FU, timing of
recurrence ormetastatic disease, and, for PTFU patients, atten-
dance at a SMworkshop (yes/no).
Outcome measures
Generic health related quality of life (HRQoL) was measured
with EQ-5D-5 L. Scores for each of five domains (mobility,
self-care, usual activities, pain, anxiety / depression) are com-
bined and converted into a summary utility index; a maximum
score of 1 indicating “full health” (no problems on any do-
main). Participants also completed the EQ-5D visual analogue
scale (range 0–100 best possible health) [19, 20]. Cancer-
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specific QoL was measured using the Functional Assessment
of Cancer Therapy: General (FACT-G) yielding four function-
al subscales (physical, social, emotional, functional
wellbeing); higher scores indicate better functioning. [21],
and FACT-C Colorectal Cancer Subscale (CCS) higher score
indicates better functioning [22].
A tool was designed for this study to assess patient experi-
ence of follow-up care, with 8 items generated from a review
of follow-up evaluations, covering: reassurance, who to con-
tact with problems, comfort about contacting health profes-
sionals (HPs) with problems, feelings of isolation, thorough-
ness of care, ability to ask questions, sufficient time fromHPs,
involvement in care decisions. [11, 12, 23]. Responses were
scored 0 to 100 (best). Respondents also rated if care was
acceptable (yes/no/unsure); met their expectations
(exceeded/met/fell short); and their perception of service qual-
ity (excellent/very good/good/fair/poor).
Sample size calculation
The primary outcome was the FACT-G. Other related studies
have observed pertinent survivorship issues following com-
pleting treatment for CRC, suggest a standard deviation (SD)
of 14.6 [24] for FACT-G within the first year after surgery. In
order to detect an underlying difference of 10 points in FACT-
G whilst making no assumption about statistically significant
difference direction, using a two-sided test with size =5% and
power = 80%, required at least 35 patients in each follow-up
regime (the pre and post change cohorts). With six months
planned for recruitment for Cohort A (OPFU), a sample of
35 was considered achievable, even allowing for up to 40%
dropout [25–27]. However, in order to conduct a valid com-
parison between OPFU and PTFU, a larger cohort was
deemed necessary for Cohort B because clinicians would not
enrol all patients directly into PTFU. Assuming at least one in
three patients is in PTFU by T2, and a dropout rate of not more
than 40% by T2, at least 175 patients needed to be recruited to
Cohort B to acquire at least 35 PTFU patients at T2.
Data analyses
Baseline characteristics of responders and non-responders
were compared. Patients in the post-change B cohort, who
started follow-up in PTFU or had been transferred by clini-
cians to PTFU by T2, were assigned to group B2 for analysis.
Patients remaining in OPFU (B) at T2 were assigned to group
B1. Summary statistics (numbers, proportions, means, and
standard deviations) were calculated for all variables at base-
line and T2, and comparisons between follow-up regimes
were conducted using appropriate statistical tests (chi-square
for categorical variables, Fisher’s exact test for dichotomous
variables when an expected cell count of <5 was encountered,
unpaired t-test for continuous variables, Mann-Whitney U test
for ordinal variables). Forward linear regression modelling
was undertaken to explore the effect on patient outcomes
(EQ-5D utility index, FACT-G, general QoL score, additional
colorectal cancer concerns score (CCS)) after different expo-
sure lengths to PTFU while controlling for demographic fac-
tors, co-morbid conditions, and clinical management.
Economic evaluation
The NHS perspective was primarily adopted, comparing costs
of OPFU with PTFU in British Pounds, 2013. Two factors
were considered: impact on direct costs, reflecting replace-
ment of clinic follow-up visits in OPFU, by self-
management in PTFU; unscheduled service use by patients,
to explore if removal of outpatient clinic access was associated
with increased visits to other health professionals. Resources
involved in delivering OPFU and PTFU were obtained from
clinic protocols and health professionals, covering the first
year of follow-up. Costs were attributed to staff resources
using validated national scales [28], and costs of facilities
and other physical resources based on actual expenditures.
To measure service utilisation, patients were asked at each
time point to retrospectively self-report health service use
since completing the last questionnaire, using a modified
Client Service Receipt Inventory [29]. To minimise confound-
ing, since some patients moved from OPFU to PTFU between
T0 and T2, the analysis period was confined to between T1
and T2. Paired group comparisonwas undertaken (Avs. B; B1
vs. B2; A vs. B2), covering utilisation of the most commonly
used services. To assess personal costs, information was re-
quested on travel to clinic appointments, whether accompa-
nied by others, and time lost fromwork. Travelling distance to
the hospital was calculated using postcodes.
Ethical considerations
The National Research Ethics Service judged this to be a ser-
vice evaluation. Governance approval was obtained from the
Trust Research and Development Department; the study was
conducted according to the ethical principles of informed con-
sent and assurance of confidentiality. Storage and processing
of data conformed to the Data Protection Act 2000.
Results
Recruitment and retention
Of 124 patients sent baseline questionnaires in Cohort A,
75 (60.5%) were returned in a timely manner; 176 of 239
(73.6%) were returned in Cohort B. Not all patients
responded at subsequent time periods; 53 (70.7%) and
79 (44.9%) responses were analysable at T2 respectively
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(Figs. 1 and 2). Of the 176 patients recruited into the
second phase of the study, there were 31 in PTFU at T0;
34 had crossed over by T1, a further 14 had crossed over
by T2, and a further 5 at T3.
Comparison of the 251 responders with 112 non-
responders at baseline revealed no significant difference
in age, sex, or deprivation. Comparison of the character-
istics of 132 participants at T2 against the remaining 119
baseline patients from whom a T2 questionnaire was not
obtained, showed that those not in the analysis at T2
were more likely to have a recurrence or metastatic dis-
ease (data not shown).
Identified too late to send 
(n=10) 
Exclusion criteria  (n= 7) 
Cohort A Recruitment 
Identified as appropriate 
(n= 141)
Deceased (n =0) 
Recurrence/metastatic disease 
(n =3) 
Declined (n=10) 
Non responder (n =22) 
Baseline Qs returned (n= 75) 
Returned too late to use( n = 12)
3 
Baseline questionnaires 
sent (n= 124)  
T0 
Developed recurrence or 
metastatic disease (n=2) (5)
1 
Deceased( n = 2)          (2)
1
Recurrence/metastatic 
disease ( n = 1)          (6)
1
Declined(n = 4)         (14)
1 
Not sent( n = 3)
2 
4 month Qs returned (n = 60) 
Returned too late to use( n= 10)
3 
Non responder(n = 8) 4 month questionnaire sent 
(n = 84) 
T1 
Developed recurrence or 
metastatic disease(n=2)     (8)
1
Deceased (n=1)               (3)
1
Recurrence/metastatic 
Disease (n=1)                  (9)
1 
Declined( n= 2)       (16)
1
Not sent( n= 6)
2 
8 month Qs  returned (n= 53) 
Returned too late to use( n = 6)
3 
Non responder( n = 6) 
8 month questionnaire 
sent( n = 69) 
T2 
12 month questionnaire 
sent( n = 50) 
T3 
12 month Qs returned( n=41) 
Returned too late to use( n=4)
3 
Non-responder( n=2) 
Incomplete cases n=36(41% of 
consented) 
Completed 3 Qs n=15(17%  of 
consented) 
Completed 2 Q n=7(8% of 
consented) 
Completed baseline Q n=14(16%) 
of consented) 
Complete cases analysed 
(n=39) 
% sent baseline 31% 
% returned baseline 45% 
Complete cases but 1 or 
more Qs returned too late 
(n=4) 
Recurrence/metastatic 
disease (n=0)                    (9)
1
Deceased(n=0)               (3)
1
Recurrence/metastatic 
disease( n=0)                  (9)
1
Declined(n= 3)               (19)
1 
Not sent (n=20)
2
1
Cumulative totals underlined 
2 
indicates: Qs not sent because of 
researcher error; clinician 
withdrawals; patient withdrawals 
3 
Indicates Qs received too late for 
timing period 
Fig. 1 Flow chart of recruitment
and retention of patients in Cohort
A
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Baseline comparison of groups
Comparison of Cohorts A (n = 75) and B (n = 176) at baseline
showed a significantly higher proportion of Cohort B patients
had received chemotherapy, and a significantly higher propor-
tion of Cohort A patients reported having arthritis. The groups
did not differ on socio-demographic characteristics (mean age
72 years, 40% women) or outcome measures (Table 1).
At baseline, most of the 176 patients in Cohort B were still
in OPFU (145 vs. 31 in PTFU). No significant differences
were found in socio-demographic characteristics of patients
in B1 and B2. Patients retained in OPFU (B1) compared to
Identified too late to send 
(n=35) 
Exclusion criteria  (n= 7) 
Cohort B Recruitment 
Identified as appropriate 
(n= 281)
Deceased (n =0) 
Recurrence/metastatic disease 
(n =2) 
Declined (n=21) 
Non responder (n =38) 
Baseline Qs returned (n= 176) 
Returned too late to use( n = 4)
3 
Baseline questionnaires 
sent (n= 239)  
T0 
Developed 
recurrence/metastatic disease 
(n=10) (12)
1 
Deceased( n = 3)          (3)
1
Recurrence/metastatic 
disease ( n = 4)          (16)
1
Declined(n = 4)         (25)
1 
Not sent( n = 33)
2 
4 month Qs returned (n = 118) 
Returned too late to use( n= 3)
3 
Non responder(n = 6) 4 month questionnaire sent 
(n = 138) 
T1 
Developed recurrence or 
metastatic disease(n=2)               
(18)
1
Deceased (n=1)               (3)
1
Recurrence/metastatic 
Disease (n=1)                  (9)
1 
Declined( n= 2)       (16)
1
Not sent( n= 6)
2 
8 month Qs  returned (n= 79) 
Returned too late to use( n = 6)
3 
Non responder( n = 6) 
8 month questionnaire 
sent( n = 87) 
T2 
12 month questionnaire 
sent( n = 51) 
T3 
12 month Qs returned( n=44) 
Returned too late to use( n=0)
3 
Non-responder( n=5) 
Incomplete cases n=135(75% of 
consented) 
Completed 3 Qs n=38(21%  of 
consented) 
Completed 2 Q n = 42 23% of 
consented) 
Completed baseline Q n=55(31%) 
of consented) 
Complete cases analysed 
(n=41) 
% sent baseline 17% 
% returned baseline 23% 
Complete cases but 1 or 
more Qs returned too late 
(n=0) 
Recurrence/metastatic 
disease (n=0)                    (9)
1
Deceased(n=0)               (3)
1
Recurrence/metastatic 
disease( n=1)                 (19)
1
Declined(n= 2)               (27)
1 
Not sent (n=68)
2
1
Cumulative totals underlined 
2 
Indicates: Qs not sent because of: 
researcher error; clinician 
withdrawals; patient withdrawals; 
patients identified after end of study 
enrollment 
3 
Indicates Qs received too late for 
timing period 
Fig. 2 Flow chart of recruitment
and retention of patients in Cohort
B
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those selected for PTFU (B2) were more likely to have re-
ceived chemotherapy, radiotherapy, and multiple treatments.
They reported lower self-rated health and physical wellbeing,
and worse CCS scores (Table 1)
Outcomes at T2
QoL outcomes were not significantly different between
Cohorts A and B at T2. Compared to patients in B1
(OPFU), those in B2 (PTFU) had significantly better
HRQoL and CCS scores (Table 2). Regression modelling
identified a high number of LTCs as the dominant factor as-
sociated with adverse HRQoL outcomes; this was offset by a
positive effect for heart disease(HD). Chemotherapy negative-
ly affected CCS scores. Patients in work reported worse CCS
scores. Time spent in PTFU was not significantly associated
with any outcome. The models explained less than 20% of the
variation (Table 3).
There were no significant differences in experience of
follow-up care between OPFU (A and B1) and PTFU (B2)
with respect to reassurance, access to specialist support, ability
to ask questions, time spent with doctors/nurses, and involve-
ment in decision-making. More patients in PTFU (36/37;
97.3%) found their follow-up to be acceptable (vs. not/unsure)
than patients in OPFU (24/32; 75%) (p = 0.010). There were
no significant differences between groups regarding quality of
care or the extent to which it met expectations; most reported
high satisfaction (Table 4).
Costs and service utilisation
Detailed analysis of the patient pathways under OPFU
and PTFU showed that PTFU was up to £142.24 per pa-
tient more expensive than OPFU in the first year. Savings
in outpatient appointments in PTFU were outweighed by
the costs of the self- management workshop and remote
surveillance (Online Resource 3 Table, of Resources and
Costs). No significant differences were found between
utilisation of community and hospital services for any
group comparison (data not shown), except GP visits were
higher for OPFU patients than PTFU patients (1.84 vs.
1.08 monthly visits, p = 0.024). Most patients (76.9%)
reported travelling to clinic by car, the mean (SD) round
trip distance between home postcodes and the hospital
being 18.73 (12.82) miles. Applying the NHS mileage
reimbursement rate (2014) of 50.5p per mile, a move to
PTFU would save £28.38 per patient in the first year
(assuming OPFU involves four clinic visits vs one in
PTFU). The majority (87.9%) were mostly or sometimes
accompanied to clinics so additional savings might arise
for companions (22.3%) taking time off work.
Discussion
This studymakes an important contribution to our understand-
ing of the impact of introducing PTFU for CRC survivors.
When the new model was launched, clinicians’ choices of
follow-up model were influenced by patients’ disease and
treatment characteristics, health outcomes and symptom bur-
den. When PTFU was introduced, almost one half (48%) of
patients were enrolled in PTFU within 8 months of entering
follow-up (mean time from final treatment to entering PTFU
of 3.75 months). This pattern is similar to findings from three
other NHS hospitals piloting stratified follow-up for colorectal
patients, where 40–45% were judged able to self-manage 4–
6 months’ post-treatment or reversal of stoma [30], and a
study of remote surveillance for post-resection patients, which
enrolled 50% in the new model [31]. As a new practice model
early in its implementation, the role of clinician attitude and
culture may have limited PTFU enrolment in our study, re-
quiring time to evolve so that trust with the new system can be
established [10]. Patient choice may also have influenced se-
lection of follow-up model [32].
Since the evaluation covered the early period post-treat-
ment, the majority of the PTFU group were patients post-
surgical resection who had not undergone chemotherapy.
Patients who were not enrolled in PTFU were found to have
poorer HRQoL and cancer specific QoL, which may explain
why these patients made more visits to their general practi-
tioner than did PTFU patients. It is clear that treatment factors
are important predictors of patient outcomes. For patients in
this study, chemotherapy was predictive of poorer cancer spe-
cific QoL and colorectal concerns, a finding consistent with
other studies investigating QoL in CRC patients [33].
Eight months after the end of treatment, having one ormore
LTCs was the most dominant negative influence on HRQoL,
cancer specific QoL, and colorectal concerns. This finding is
consistent with other studies, and accounts for activity limita-
tions, and participation restrictions (in work, daily activities)
[25–27]. The importance of bowel symptoms such as diar-
rhoea and faecal control and QoL have been reported before
[27, 34], and coping with these symptoms in the workplace
probably accounts for the negative association of colorectal
concerns with being in work. The positive effect on colorectal
concerns by HD may be related to behaviours learned to self-
manage heart disease as a LTC, being used to cope with the
adverse effects of CRC treatment on bowel control. A propor-
tion of participants with HD will have attended a cardiac re-
habilitation programme, having benefits, which equipped par-
ticipants to deal with another serious condition. [35]
Follow-up model was not a significant influence on out-
comes in this study, possibly because the FU period was too
short to make a significant impact on patients. Findings by
Siddika et al. [31] indicate patient satisfaction with remote
surveillance is high in years 3 and 4 of follow-up. Few other
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Table 1 Socio-demographic, clinical characteristics, treatment, and patient reported outcomes according to model of follow-up at T0: Cohort A vs
Cohort B, and Cohort B1 vs Cohort B2
Cohort Difference
P-value
Cohort Difference
P-value
Characteristics A (n = 75) B (n = 176) B1 (n = 92) B2 (n = 84)
Socio-demographic Age mean(SD) 72.9 (8.7) 71.6 (10.6) 0.340a 71.1 (10.4) 72.1 (10.8) 0.524a
Gender = Female (%) 27(36) 74(42) 0.371b 38(41) 36(43) 0.835b
Ethnicity = White (%) 70(97) 171(99) 0.156b 89(99) 82(100) 1.000b
Domestic status =Live alone (%) 21(30) 38(22) 0.347b 14(16) 24(30) 0.155b
Education, Highest
qualification
No qualifications (%) 25(42) 56(36) 0.658c 31(39) 25( 32) 0.296c
GCE/O Level (%) 8(13) 25(16) 14(18) 11(14)
A-Level (%) 4(7) 14(9) 5(6) 9(12)
Vocational qualification 15( 25) 42(27) 22(28) 20( 26)
Working status Unable to work (%) 6(9) 11(6) 0.275b 7( 8) 4(5) 0.554b
Able to work (%) 7(10) 31(18) 14(16) 17(21)
N/A Retired (%) 56(81) 128(75) 67(76) 61(74)
Hours worked last week (SD) 20.55(16.07) 25.05(15.75) 0.560a 21.08(15.52) 28.28(15.67) 0.227a
Hours normally worked per week mean(SD) 26(13.38) 30.19(13.2) 0.492a 27.05(13.44) 32.5(12.99) 0.307a
Days sick leave in past 4 weeks mean (SD) 2 (4.47) 3.76 (7.75) 0.630a 5.1 (7.64) 2.87 (7.95) 0.492a
Clinical Months, first diagnosis to T0 mean (SD) 7.6(4.66) 6.51(3.72) 0.075a 7.81(4.11) 5.09(2.59) <0.001a
Months, end of last treatment to T0 mean(SD) 3.08(2.54) 2.22(1.69) 0.010a 2.53(1.81) 1.9(1.5) 0.015a
Months, end of last treatment to
PTFU mean(SD)
- - - - 3.75(3.61) -
Number of LTCs mean (SD) 1.1 (1.19) 0.95 (1.07) 0.348a 1.02 (1.14) 0.88 (0.99) 0.372a
Diabetes ( %) 10(14.3) 25(15) 0.892b 15(17.4) 10(12.3) 0.356b
Heart Disease (%) 7(10) 21(12.6) 0.575b 10(11.6) 11(13.6) 0.704b
COPD (%) 2(2.9) 6(3.6) 1.000d 3(3.5) 3(3.7) 1.000d
Arthritis (%) 17(24.3) 23(13.8) 0.049b 10(11.6) 13(16) 0.407b
Depression (%) 3(4.3) 6(3.6) 0.726d 3(3.5) 3(3.7) 1.000d
High blood pressure (%) 27(38.6) 48(28.7) 0.138b 30(34.9) 18(22.2) 0.071b
Last treatment received Surgery (%) 59(84) 117(70) 0.114b 47 (53) 70(90) <0.001b
Chemotherapy (%) 10(14) 43(26) 36(40) 7( 9)
Radiotherapy (%) 1(1) 3(2) 3(3) 0(0)
Other (%) 0(0) 4(2) 2(2) 2(3 )
Additive treatment Surgery only (%) 52(69) 107(61) 0.024b 40(43) 67(80) <0.001b
Surgery + Chemotherapy (%) 8(11) 48(27) 36(39) 12(14)
Surgery + Chemotherapy +Radiotherapy (%) 10(13) 16(9) 12(13) 4( 5)
Surgery + Radiotherapy (%) 3(4) 5(3) 4(4) 1(1)
Surgery + Microwave Ablation (%) 1(1) 0(0) (0) (0)
Surgery +Chemotherapy +
Microwave Ablation (%)
1(1) 0(0) (0) (0)
Previous cancer diagnosis Yes (%) 8(11) 14(8) 0.487b 9(10) 5( 6) 0.348b
No (%) 67(89) 162(92) 83(90) 79(94)
Metastatic disease removed prior to T0: No (%) 72(96) 171(97) 0.699d 87(95) 84(100) 0.060d
Patient Reported
Outcome Measures
EQ5D-5 L index, mean(SD)
[worst −0.594,best 1]
0.8(0.21) 0.82(0.17) 0.480a 0.79(0.16) 0.86(0.17) 0.010a
EQ5D-5 LVAS mean(SD) [worst 0–100] 76.57(21.16) 77.35(16.95) 0.758a 73.5(18.55) 81.73(13.79) 0.001a
FACT:PWB mean(SD) [worst 0, best 28] 24.05(4.9) 24.7(3.74) 0.307a 23.91(4.26) 25.59(2.82) 0.003a
FACT:SWB mean(SD) [worst 0, best 28] 22.97(5.41) 22.6(6.13) 0.662a 23.16(4.98) 21.99(7.15) 0.224a
FACT:EWB mean(SD) [worst 0, best 24] 20.68(3.96) 20.52(3.28) 0.744a 20.23(3.05) 20.82(3.5) 0.246a
FACT:FWB mean(SD) [worst 0, best 28] 20.52(8.02) 20.63(6.65) 0.705a 19.92(6.34) 21.65(6.88) 0.060a
FACT: CRCs mean(SD) [worst 0, best 28] 21.38(5.12) 22.06(4.55) 0.301a 20.98(5.06) 23.23(3.62) 0.001a
FACT-G total mean(SD) [0 worst, best 108] 89.81(16.35) 89.08(14.15) 0.736a 88.22(12.84) 90.01(15.48) 0.429a
Cohort A: Pre-change outpatient follow-up; Cohort B: Post-change outpatient follow-up + PTFU;
Cohort B1: Post-change outpatient follow-up only; Cohort B2: Post-change PTFU only
a Unpaired t test
b Chi-square test
cMann-Whitney U test
d Fisher’s Exact test
Abbreviations: GCE/O level = General Certificate of Education, Ordinary level; A-level = Advanced level; PTFU = patient-triggered follow-up;
LTCs = Long term conditions; COPD = Chronic obstructive pulmonary disease; EQ5D-5 L = Euro-Qol Group index; VAS = visual analogue scale;
FACT = Functional Assessment of Cancer Treatment; PWB = physical wellbeing subscale; SWB = social wellbeing; EWB = emotional wellbeing;
FWB = functional wellbeing; CRCs = additional colorectal cancer concerns; FACT-G = Functional Assessment of Cancer Therapy- General Total QoL
score
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studies have evaluated PTFU as an alternative to OPFU, but
those evaluating breast follow-up found no difference in QoL,
psychological morbidity, [11, 12] or satisfaction [31]. No
study has indicated PTFU is less safe than routine OPFU,
and a recent 5-year remote surveillance study of surgically
treated CRC patients [31] found the approach safe and cost-
effective. The presence of symptom morbidity interacting ad-
versely with LTCs (over a quarter of patients in this study had
two or more) identifies a subgroup of patients where nurse-led
risk assessment could lead to tailored follow-up plans for sur-
vivors who may require more active support. This is a key
finding; as more services move towards risk-stratified ap-
proaches to follow-up care, defining the individual dimen-
sions of supportive care required by all CRC survivors is an
essential precursor to relevant supportive care services [36].
After active treatment, survivors can experience sudden and
unforeseen anxiety and distress in the transition to follow-up
care [37].Evidence froma surveyofpatient-reportedoutcomes
suggests information and preparation for follow-up is limited, a
qualitative analysis of comments leading researchers to con-
clude“patientsbeingcutadrift”bythehealthsystemafteractive
treatment [38]. An important and positive finding from our
study demonstrates that most patients were reassured by their
follow-up, found their care either exceeded or met their expec-
tations, and reported excellent or very good quality of care.
More PTFU than OPFU patients found their care to be
acceptable. PTFU provided ingredients evidenced to be very
important to patients: convenience, tailored information [39],
reassurance through a formal process of quick access to spe-
cialist advice and tests [37], continuity of care-provider (CNS)
[37], and a trusting relationship with specialist nurses [39].
Data available from the study can be utilised to modify and
improve the service and address the needs of the small sub-
group who found aspects of their care not acceptable.
Table 2 Patient reported outcomes according to model of follow-up at T2:Cohort A vs Cohort B, and Cohort B1 vs Cohort B2
Cohort Difference
P-value
Cohort Difference
P-value
Characteristics A (n = 53) B (n = 79) B1 (n = 38) B2 (n = 41)
Socio-demographic/Clinical Age at T2 mean(SD) 72.9 (8.7) 71.6 (10.6) 0.340a 71.1 (10.4) 72.1 (10.8) 0.524a
Months from first diagnosis
to T2 mean (SD)
15.05(4.31) 14.21(3.24) 0.201a 15.55(3.6) 12.96(2.26) 0.003a
Months from end of last
treatment to T2 mean(SD)
11.08(2.45) 10.47(1.77) 0.128a 10.68(1.81) 10.29(1.73) 0.333a
Months from end of last
treatment to PTFU
mean(SD)
Not
applicable
6.28(4.10) Not
applicable
15.52(2.42) 5.38(2.94) <0.001a
Additive Treatment Surgery only (%) 38(72) 49(62) 0.123b 16(42) 33(80) 0.004b
Surgery + Chemo (%) 4(8) 19(24) 14(37 5(12)
Surgery + Chemo +RT (%) 6(11) 8(10) 5(13) 3(7)
Surgery + RT (%) 3(6) 3(4) 3(8) 0(0)
Surgery + MA (%) 1(2) 0(0) 0(0) 0(0)
Surgery + Chemo + MA (%) 1(2) 0(0) 0(0) 0(0)
Patient reported outcomes EQ5D-5 L health score
mean(SD)
0.81(0.23) 0.83(0.17) 0.480a 0.79(0.16) 0.87(0.15) 0.033a
EQ5D-5 LVAS mean(SD) 81.58(18.45) 78.5(15.56) 0.302a 73.57(16.66) 83.07(13.07) 0.006a
FACT:PWB mean(SD) 24.19(5.6) 25.31(3.7) 0.199a 24.56(3.96) 26.05(2.19) 0.043a
FACT:SWB mean(SD) 22.92(4.65) 21.7(6.35) 0.227a 21.64(6.53) 21.82(6.25) 0.899a
FACT:EWB mean(SD) 20.94(3.39) 20.28(3.13) 0.269a 19.82(3.23) 20.73(2.99) 0.205a
FACT:FWB mean(SD) 21.38(6.92) 20.97(5.7) 0.715a 19.46(5.72) 22.4(5.37) 0.022a
FACT: CRCs mean(SD) 22.2(4.89) 22.66(3.51) 0.566a 21.77(3.75) 23.55(3.05) 0.026a
FACT-G total mean(SD) 91.98(15.01) 88.31(13.3) 0.163a 85.48(13.58) 91.15(12.56) 0.063a
Cohort A: Pre-change outpatient follow-up; Cohort B: Post-change outpatient follow-up + PTFU;
Cohort B1: Post-change outpatient follow-up only; Cohort B2: Post-change PTFU only
a Unpaired t test
b Chi-square test
Abbreviations: PTFU = patient-triggered follow-up; Chemo = chemotherapy; RT = Radiotherapy; MA = microwave ablation;
PROM = patient reported outcome measurement; EQ5D-5 L = Euro-Qol Group health score[worst −0.594,best 1]; VAS = visual analogue scale[worst 0–
100]; FACT = Functional Assessment of Cancer Treatment; PWB = physical wellbeing subscale[worst 0, best 28]; SWB = social wellbeing[worst 0, best
28]; EWB = emotional wellbeing[worst 0, best 24];FWB = functional wellbeing[worst 0, best 28];CRCs = additional colorectal cancer concerns[worst 0,
best 28]; FACT-G = Functional Assessment of Cancer Therapy- General Total QoL score[0 worst, best 108]
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Expectations of care were met or exceeded for all patients
in PTFU but were not realised by a small number of patients in
OPFU. This may reflect that, in contrast to PTFU patients who
attend a self-management workshop, those in OPFU receive
no formal explanation of the follow up processes. Also, OPFU
patients are more troubled by symptoms. Routine clinic
check-ups and tests intended to allay anxiety, provide only
temporary reassurance for some, who then have an anxious
wait for their next clinic visit [37]. Moreover, support for on-
going symptoms, and concerns after treatment, may have been
lacking [40].
The present study responded to the need to redesign existing
services to improve patient experience and address the rising
demand for follow-up that puts limited resources under pres-
sure. Exploring impact on resource use and costs is important
when redesigning follow-up care models [41]. After one year,
released clinical capacity in the study setting enabled the estab-
lishment of a nurse-led service for patientswith complexneeds.
PTFUwas, however, slightlymoreexpensive thanOPFUin the
first year, largelydue to a self-managementworkshop and costs
associated with staff organising remote surveillance. If fixed
costs of training and IT software had been included in the
Table 3 Regressions at T2
Outcome at T2 [range] Constant Ba Predictor P - value R2
EQ5D-5 L [−0.594 to 1(best)] 0.877 -0.066b Number of longstanding conditions
including ‘other’ at T2
<0.001 0.121
FACT-G at T2 [0 to 108(best)] 95.225 -5.266c Number of longstanding conditions
including ‘other’ at T2
<0.001 0.168
+13.226d Had heart disease at T2 0.008
-5.741e Had chemotherapy by T0 0.047
Colorectal Cancer Concerns [0 to 28(best)] 24.227 -3.197f In work at T2 0.001 0.188
-1.240g Number of longstanding conditions
including ‘other’ at T2
0.003
+3.637h Had heart disease at T2 0.009
aUnstandardised coefficient
b Each longstanding condition reduces EQ5D score by 0.066, so 3 longstanding
conditions, score falls (worse by 0.2 points)
c Each longstanding condition reduces FACT-G score by 5.266 points, so 3
longstanding conditions, score falls (worse by 15.8 points)
d If heart disease present, FACT-G score rises (better by 13.226 points)
e If had chemotherapy, FACT-G score falls (worse by 5.741 points)
f If in work, colorectal cancer concerns score falls (worse by 3.197 points)
g Each longstanding condition reduces colorectal cancer concerns score by 1.24
points, so 3 longstanding conditions, score falls (worse by 3.72 points)
h If heart disease present, FACT-G score rises (better by 3.637 points)
EQ5D-5 L EurolQol health index; FACT-G functional assessment of cancer therapy -general
Table 4 Patient reported quality, and expectations of follow-up care at T2: Cohort A, B1, and B2
Quality of care Expectations about care
Cohort Excellent Very good Good Fair Poor Total Exceeded Met Fell short Total
n % n % n % n % n % n % n % n %
Aa OPFU 16 35.6 15 33.3 9 20 4 8.9 1 2.2 45 9 21.4 31 73.8 2 4.8 42
B1b OPFU 6 17.1 16 45.7 7 20 5 14.3 1 2.9 35 4 12.1 25 75.8 4 12.1 33
B2c PTFU 10 29.4 16 47.1 6 17.6 2 5.9 0 0 34 5 16.1 26 77.4 0 0 31
Mann Whitney U test A and B1 (OPFU) vs. B2 (PFTU) at T2 p = 0.371 p = 0.542
B1 (OPFU) vs. B2 (PTFU) at T2 p = 0.110 p = 0.165
a Pre-service change outpatient follow-up
b Post-service change outpatient follow-up
c Post-service change patient triggered follow-up
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calculations, excess costs would have been greater. Economies
of scale in the delivery of the workshop may be realised in the
future as the service reaches capacity. Taking a five-year per-
spective, up to ten outpatient appointments could be saved by
PTFU. In addition tohealth care systemsavings,PTFU reduces
time and financial costs for patients associated with having a
cancer diagnosis [42].
The strengths of the study are its prospective longitudinal
design and use of validated tools for comparing QoL [19–22]
in post-treatment CRC survivors experiencing novel and stan-
dard follow-up care. Important insights on stratification of
patients post- treatment and perceptions of care quality were
provided which if addressed should improve follow-up in the
future. The new PTFU model was designed with clinicians,
and delivered by these same clinicians. It preserved clinical
judgement about the best follow-up model for their patient,
reflecting a real world embedded service evaluation [43].
Thestudyhasseveral limitations.Datacollectionof thepost-
change cohort was started soon after PTFUwas commenced in
order to achieve planned recruitment within the study period.
Clinicians made the decision to enrol patients in PTFU, but
readiness to change was limited and willingness evolved with
time. This had an impact on the size of this group. It alsomeant
that patients inOPFUwere generally sicker, making it difficult
to interpret the differences in patient and health service out-
comes. Transfer of patients from OPFU to PTFU at differing
times resulted in contamination of the PTFUgroup. In the anal-
ysis, any patient who entered PTFU before T2 was considered
to be in the PTFU group but thismasked considerable variabil-
ity in timing. Also, delayed distribution and return of question-
naires meant some assessments deviated from the planned
schedule of data collection. Data collection was curtailed due
to time pressures, therefore numbers of patients were not sent
follow-up questionnaires at T1/2/3. The decision to undertake
the analysis at T2 (8 months post final treatment), prevented
comparison of the 12-months outcomes for the two models
was pragmatic, in that loss to follow-up gradually reduced
group sizes. Attrition at T2, particularly in group B was high
due to recurrence or metastatic disease.
In conclusion, enrolment of patients in PTFU is largely a
clinical decision determined by the pace of patient recovery.
This model of PTFU, introduced by a self-management work-
shop [44], was found acceptable to patients, and will allow
low, and some moderate risk patients to undergo five-year
surveillance without routine clinic attendance but with access
to clinical input if necessary. Cancer specific QoL and
HRQoL outcomes were influenced by side effects of treat-
ments and the presence of LTCs, rather than the follow-up
model, and should lead to the promotion of targeting tailored
supportive care for those at risk.
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